[OTTAWA] BIOTECanada, the national industry association representing Canada’s biotechnology ecosystem, is pleased to announce the appointment of Ian Mortimer, President and CEO of Xenon Pharmaceuticals, to its Board of Directors at the association’s Annual General Meeting. As the voice of Canada’s biotechnology sector, BIOTECanada continues to strengthen the leadership driving its efforts to grow a globally competitive biotech ecosystem. Mortimer’s appointment underscores the organization’s commitment to advancing its strategic priorities focused on regulatory modernization and investment attraction.
“Ian brings extensive executive and capital market experience to the Board of Directors, having played a key role in the growth of several public biotech companies, including Xenon Pharmaceuticals, which has grown from a private company to Canada’s largest publicly traded biotech company, now approaching Canadian ‘anchor-company’ status,” said Oliver Technow, President & Owner of Morpheus Consulting and Chair of the Board of Directors.
“Ian’s track record of scaling biotech companies and navigating complex industry dynamics will further strengthen the depth of expertise on our Board,” said Wendy Zatylny, President & CEO of BIOTECanada. “As we continue to advocate for increased availability of investment capital and ambitious regulatory leadership, his experience will be a valuable asset in shaping the path ahead,” added Zatylny.
BIOTECanada’s Board reflects the diversity of its membership, and the full biotech ecosystem: from research and start-ups to commercialization, global companies, and investors. Click here for a full list of BIOTECanada’s Board of Directors.